Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (6023)	11/20/2004 10:44:55 AM
From: rkrw	Read Replies (1) \| Respond to of 10345

Fred, They got indication for 2nd and 3rd line with no egfr restriction. What was your expectation? If basing conclusions on immediate aftermath, does that mean idev got a bad label (down 25% within 2 weeks)? If Elan goes down day one of approval, what will that mean to you?

To: fred hayes who wrote (6023)	11/20/2004 2:52:22 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 10345

>> but it sure looks like the perception of a more limited market drove the downturn << Yup. But.... (1) "perception" will rule for a day or ninety until reality kicks in. Not saying that the current capitalization is justified, that reality will turn the stock. But the news was all good; (2) 9% isn't much of a haircut... this is biotech; and (3) "perception" could not have been framed more clearly/accurately by the DNA/OSIP. It's not their fault if investors pushed beyond the frame. We have a new weapon in the battle against cancer. Let's rejoice, and let product sales take the stocks where they may. DNA trades at a P/E of 75...... biotechs are leveraged to an extreme, and a little fear mongering goes a long way.